US Based Innovator Chooses IVRCC’s customized IWRS Patient Enrollment and Randomization Management Applications
Saratoga Springs, NY JANUARY 13 , 2014 –- An innovative specialty pharmaceutical company, focused on the development and commercialization of proprietary medicines from their own research efforts to make significant advances in the fields of thrombosis and other hematologic diseases, has selected IVRCC to collaborate on two pivotal phase 3 studies in 2014. Choosing IVRCC’s technology solutions reflects their commitment to powerful applications that support the development of therapies to prevent and treat certain medical conditions.
Using the easy and familiar interface of a readily available Web application, clinical personnel are able to enter, and review records of their date/time stamped enrollment events immediately in real-time. Subsequent randomization, and specialized discontinued subject replacement module randomization using an algorithm to ensure complete blind and adequate evaluable data, is flawlessly executed through IVRCC’s custom programmed automated system.
“IVRCC’s flexible applications provide clinical trial personnel the ability to manage critical trial events, including complicated randomizations, easily, automatically and in a protocol directed timely manner,” says Nancy Hudak, Business Development Manager. “Our robust, self-hosted applications are carefully monitored 24/7 for continuous uninterrupted service to ensure no delay of timed trial activities. We are very excited to be working with this biopharmaceutical leader to support their development of novel biomarker and genetic treatments to address significant unmet needs,” Hudak adds.